Sitafloxacin: In bacterial infections

Drugs

Volumn 71, Issue 6, 2011, Pages 731-744

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Bacterial infections; Sitafloxacin, general

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM CARBONATE; CIPROFLOXACIN; FERROUS SULFATE; GATIFLOXACIN; LEVOFLOXACIN; MAGNESIUM OXIDE; MOXIFLOXACIN; RANITIDINE; SITAFLOXACIN; THEOPHYLLINE; TOSUFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BRONCHITIS; CHLAMYDIASIS; COMMUNITY ACQUIRED PNEUMONIA; CREATININE CLEARANCE; CYSTITIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EAR NOSE THROAT DISEASE; EOSINOPHIL COUNT; GINGIVA DISEASE; GONOCOCCAL URETHRITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; JAW DISEASE; LARYNGITIS; LARYNGOPHARYNGITIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; NONSPECIFIC URETHRITIS; OPTIMAL DRUG DOSE; OSTEITIS; OTITIS MEDIA; PARANASAL SINUSITIS; PERIODONTITIS; PERITONSILLAR ABSCESS; PERITONSILLITIS; PHARYNGITIS; PLASMA PROTEIN BINDING; PNEUMONIA; PYELONEPHRITIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SECONDARY INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; STOMACH DISCOMFORT; TIME TO MAXIMUM PLASMA CONCENTRATION; TONSILLITIS; TOOTH INFECTION; URINARY TRACT INFECTION; UTERINE CERVICITIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CITROBACTER; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; FUSOBACTERIUM; HAEMOPHILUS INFLUENZAE; KLEBSIELLA; LEGIONELLA PNEUMOPHILA; MORAXELLA CATARRHALIS; MORGANELLA MORGANII; MYCOPLASMA; PEPTOSTREPTOCOCCUS; PORPHYROMONAS; POSIBACTERIA; PREVOTELLA; PROTEUS (ENTEROBACTERIA); PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 79955046653     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11207380-000000000-00000     Document Type: Article

References (52)

1. Hawkey PM, Jones AM. The changing epidemiology of re-sistance. J Antimicrob Chemother 2009 Sep; 64 Suppl. 1: i3-10
2. Ubukata K. Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J Infect Chemother 2003 Dec; 9 (4): 285-91 (Pubitemid 38031322)
3. Canton R, Morosini M, Enright MC, et al. Worldwide in-cidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003 Dec; 52 (6): 944-52 (Pubitemid 38008414)
4. Yokota S, Sato K, Kuwahara O, et al. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother 2002 Oct; 46 (10): 3311-5
5. Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005 Dec; 116 (6 Suppl.): S13-47 (Pubitemid 41715240)
6. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 Mar 1; 44 Suppl. 2: S27-72 (Pubitemid 46290553)
7. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011 Mar 1; 52 (5): e103-20
8. Albertson TE, Chan AL. Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis. Expert Rev Respir Med 2009 Oct; 3 (5): 539-48
9. Yamaguchi K, Ohno A, Ishii Y, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007 [in Japanese]. Jpn J Antibiot 2009 Aug; 62 (4): 346-70
10. Daiichi Sankyo Co., Ltd. Gracevit® tablets 50mg, fine granules 10%: prescribing information. Japan: 2009 Jun
11. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62 (1): 13-59 (Pubitemid 34169425)
12. Okumura R, Hirata T, Onodera Y, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quino-lone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2008 Jul; 62 (1): 98-104 (Pubitemid 351865879)
13. Onodera Y, Uchida Y, Tanaka M, et al. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. J Antimicrob Chemother 1999 Oct; 44 (4): 533-6 (Pubitemid 29490624)
14. Morrissey I, George JT. Inhibition of pneumococcal topoi-somerases by sitafloxacin. Drugs 1999; 58 Suppl. 2: 354-5
15. Tanaka M, Onodera Y, Uchida Y, et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother 1997 Nov; 41 (11): 2362-6 (Pubitemid 27467541)
16. Hoshino K, Kitamura A, Morrissey I, et al. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994 Nov; 38 (11): 2623-7 (Pubitemid 24332597)
17. Amano A, Matsuzaki K, Kishi N, et al. In vitro activity of sitafloxacin against clinical isolates in 2009 [in Japanese]. Jpn J Antibiot 2010 Dec; 63 (6): 411-30
18. Kanda H, Kurosaka Y, Fujikawa K, et al. In vitro and in vivo antibacterial activity of sitafloxacin [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 1-17 (Pubitemid 351662837)
19. Yamamoto N, Fujita J, Shinzato T, et al. In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus con-stellatus. Int J Antimicrob Agents 2006 Feb; 27 (2): 171-3 (Pubitemid 43138852)
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2008
21. Yokota S, Ohkoshi Y, Fujii N. Susceptibility and bacter-icidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Diagn Microbiol Infect Dis 2009 Sep; 65 (1): 76-80
22. Giamarellou-Bourboulis EJ, Sambatakou H, Grecka P, et al. Sitafloxacin (DU-6859a) and trovafloxacin: post-antibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus. Diagn Micro-biol Infect Dis 1999 Aug; 34 (4): 301-7 (Pubitemid 29325043)
23. Mikamo H, Kawazoe K, Sato Y, et al. Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis. J Antimicrob Chemother 1998 Jan; 41 (1): 131-3 (Pubitemid 28064263)
24. Fukuda Y, Yanagihara K, Ohno H, et al. In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. Antimicrob Agents Chemother 2006 Jan; 50 (1): 121-5 (Pubitemid 43042911)
25. Nakamura S, Yanagihara K, Araki N, et al. In vivo efficacy of sitafloxacin in a new murine model of non-typeable Haemophilus influenzae pneumonia by sterile intratracheal tube. Int J Antimicrob Agents 2009 Sep; 34 (3): 210-4
26. Kurosaka Y, Ishida Y, Yamamura E, et al. Therapeutic efficacy of sitafloxacin against Pseudomonas aeruginosa in a rat model of urinary tract infection. Drugs 1999; 58 Suppl. 2: 412-4 (Pubitemid 29500221)
27. Hong SG, Moland ES, Wickman PA, et al. In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in Gram-positive cocci. Antimicrob Agents Chemother 2007 Apr; 51 (4): 1512-4 (Pubitemid 46586840)
28. Touyama M, Higa F, Nakasone C, et al. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. J Antimicrob Chemother 2006 Dec; 58 (6): 1279-82 (Pubitemid 44884153)
29. Saito A, Watanabe A, Aoki N, et al. Phase III double-blind comparative study of sitafloxacin versus tosufloxacin in patients with community-acquired pneumonia [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 49-62 (Pubitemid 351662843)
30. Hori S, Kobayashi H, Saito A, et al. Clinical trials of sitafloxacin (DU-6859a): clinical safety profile [abstract no. L-489 plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
31. Nakashima M, Uematsu T, Kosuge K, et al. Phar-macokinetics and tolerance of DU-6859a, a new fluoro-quinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995 Jan; 39 (1): 170-4
32. Saito A, Tanigawara Y, Watanabe A, et al. Open study of sitafloxacin in patients with respiratory tract infections: PK/PD study [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 63-80 (Pubitemid 351662844)
33. Sasaki J, Hori S. Oral tissue distribution, efficacy, and safety of sitafloxacin in patients with dentistry and oral surgery infection [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 121-9 (Pubitemid 351662849)
34. Baba S, Suzuki K, Yamanaka N, et al. Efficacy and safety of sitafloxacin in patients with otorhinolaryngological infections and its tissue distribution in the otorhinolar-yngological field [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 110-20 (Pubitemid 351662848)
35. O'Grady J, Briggs A, Atarashi S, et al. Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoro-quinolone antibiotic, in healthy male and female Caucasian subjects. Xenobiotica 2001 Nov; 31 (11): 811-22 (Pubitemid 33116453)
36. 19F magnetic resonance spectroscopy. Br J Clin Pharmacol 2005 Feb; 59 (2): 244-8 (Pubitemid 40208863)
37. Nakashima M. Pharmacokinetics of sitafloxacin (DU-6859a) in healthy volunteers [in Japanese]. Jpn J Che-mother 2008; 56 Suppl. 1: 154-5 (Pubitemid 351662853)
38. Nakashima M, Kawada Y. Pharmacokinetic profiles of si-tafloxacin in patients with renal dysfunction [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 21-4 (Pubitemid 351662839)
39. Sekino H. Pharmacokinetic profiles of sitafloxacin in elderly volunteers [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 18-20 (Pubitemid 351662838)
40. Shiba K. Effect of ranitidine on sitafloxacin absorp-tion [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 32-5 (Pubitemid 351662841)
41. Shiba K. Effect of metal-ion on sitafloxacin absorption [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 25-31 (Pubitemid 351662840)
42. Niki Y, Itokawa K, Okazaki O. Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Antimicrob Agents Chemother 1998 Jul; 42 (7): 1751-5 (Pubitemid 28311574)
43. MacGowan A, Rogers C, Bowker K. The use of in vitro pharmacodynamic models of infection to optimize fluoro-quinolone dosing regimens. J Antimicrob Chemother 2000 Aug; 46 (2): 163-70 (Pubitemid 30639284)
44. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Micro-biol Infect Dis 2003 Apr; 22 (4): 203-21 (Pubitemid 36578906)
45. Kobayashi H, Watanabe A, Nakata K, et al. Double-blind comparative study of sitafloxacin versus levofloxacin in patients with respiratory tract infection [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 36-48 (Pubitemid 351662842)
46. Kawada Y, Yasuda M, Tanaka K, et al. Dose-comparative study of sitafloxacin in complicated urinary tract infections [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 92-102 (Pubitemid 351662846)
47. Kawada Y, Ishihara S, Matsui T, et al. Comparative study on sitafloxacin and levofloxacin in complicated urinary tract infections [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 81-91 (Pubitemid 351662845)
48. Kawada Y, Matsumoto T, Onodera S, et al. Clinical study of sitafloxacin in male nongonococcal urethritis [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 130-8 (Pubitemid 351662850)
49. Onodera S, Hori S. Clinical study of sitafloxacin in the treatment of male gonococcal urethritis [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 146-53 (Pubitemid 351662852)
50. Matsuda S, Noguchi M, Yasuda J, et al. Clinical study of sita-floxacin in treatment of cervicitis with Chlamydia trachomatis [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 139-45 (Pubitemid 351662851)
51. Dawe RS, Ibbotson SH, Sanderson JB, et al. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol 2003 Dec; 149 (6): 1232-41 (Pubitemid 38058100)
52. Anderson DL. Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc) 2008 Jul; 44 (7): 489-501